AJMC Staff

What we're reading, April 26, 2016: the Supreme Court could rule for new process of reviewing drug patents; new Medicaid rules announced; 7 New York insurers will expand coverage of hepatitis C drugs.

What we're reading, April 25, 2016: Marilyn Tavenner predicts steep Obamacare insurance premium hikes in 2017; the World Health Organization formally begins looking for its new leader; and the life expectancy between rich and poor young Americans narrows.

A diabetes drug may have benefits for people with chronic heart failure. Boehringer Ingelheim and Eli Lilly and Company have announced plans to investigate the use of the diabetes medicine Jardiance for heart failure with 2 outcome trials.

Stories on unsettling data on a rising suicide rate, Louisiana's Medicaid expansion efforts, and a Florida consumer education tool.

What we're reading, April 21, 2016: Congress keeps things moving on the fight against the opioid epidemic; new paper from the National Bureau of Economic Research finds Medicaid expansion has a broader societal impact; and Novartis faces stiff competition from generic version of Gleevec.

What we're reading, April 20, 2016: Tufts Health Plan will pay for hepatitis C drugs for all patients with the disease; drug advertisements don't sway consumers; and Express Scripts countersues Anthem.

What we're reading, April 19, 2016: blood-testing laboratory Theranos is now facing a criminal investigation; biosimilars may not be cheaper than brand name biologics for some seniors; and stigma and misconceptions remain regarding palliative care.

What we're reading, April 18, 2016: medical experts ask the Joint Commission to revisit its standards of pain management; study determines low-cost generics just as effective at treating hepatitis C as brand name drugs; and UnitedHealth also pulling out of Michigan Obamacare exchange.

The action, to be published Monday in the Federal Register, comes as the agency puts increased focus on long-term safety of drugs that treat diabetes and obesity, and prevent cardiovascular events.

What we're reading, April 15, 2016: troubling disparities in access to preventive care remain; new test to choose the right hepatitis C medication could save money; and upcoming loss of exclusivity for some drugs could mean big savings for the healthcare system.

What we're reading, April 14, 2016: House passes bill to speed up approval for Zika virus vaccines; spending on prescription brand name drugs grew just 2.8% in 2015; and Maine Senate passes measure to expand Medicaid.

What we're reading, April 13, 2016: scientists find possible "superhero DNA" protecting individuals from debilitating diseases; NPR shines a light on the long wait Native Americans face for healthcare; and doctors rarely discuss weight loss strategies with obese patients.

What we're reading, April 12, 2016: Zika virus scarier than initially thought; KaloBios will adopt a more transparent and "responsible" pricing model for products; and children in rural areas have more complex and expensive hospital stays.

What we're reading, April 11, 2016: UnitedHealth calls it quits for 2 Obamacare state exchanges; study finds disparities across country in lifespans of low-income people; and Hillary Clinton and PhRMA agree on one proposal to curb drug costs.

A preliminary briefing document expresses concerns over clinical benefit over existing treatments, safety, and overall risk-benefit of the drug for the subset of lung cancer patients for whom the drug has been developed.

What we're reading, April 8, 2016: Disney demanded a soda study be withdrawn; WHO wants a reduction in the price of insulin; and hospitals need better tools to flag harmful prescription drugs.

What we're reading, April 7, 2016: hospitals will help Louisiana pay for Medicaid expansion; Pfizer considers splitting the company after deal with Allergan falls through; and Pfizer gets 300 lawsuits dismissed.

What we're reading, April 6, 2016: the federal government could be doing more to alert uninsured individuals about their eligibility for subsidies; the White House will transfer leftover Ebola funds to combat the Zika virus; and Senate companion bill to 21st Century Cures Act is almost done.

Carrying weight around the midsection was associated with dysfunction of the left ventricle, according to a study presented at the American College of Cardiology.

What we're reading: new rules from the Treasury Department could derail the Pfizer-Allergan merger; false medical beliefs could lead white medical students and residents to suggest inappropriate treatment for black patients; and while prescriptions were down, sales were up for the top 10 drugs in the US.

What we're reading: California will open Medi-Cal to all low-income children regardless of immigration status; Arizona governor signs bill to follow earlier FDA guidelines for abortion-inducing drug; and the loss of 2 Obamacare provisions could result in increased premiums in 2017.

What we're reading, April 1, 2016: Federal Trade Commission files lawsuit to stop pay-to-delay deals; CMS' bundled payment initiative for joint replacement takes effect; and scientists confirm link between Zika virus and microcephaly.

What we're reading, March 31, 2016: the FDA changed guidelines for the use of the abortion pill, which could expand access; meanwhile Donald Trump isolated himself by saying women seeking abortion should face punishment; and drug makers are paying less fines for bad behavior.

What we're reading, March 30, 2016: the Supreme Court asks for more information in birth control case; Americans display lack of knowledge about Zika virus; and China provides an opportunity for drugs that fail to make it to market elsewhere.

What we're reading, March 29, 2016: the Obama administration is expected to announce new measures to combat opioid addiction; cholesterol test results from Theranos could throw off doctors' decisions; and Republicans aren't talking as much about Obamacare on the campaign trail.

A study presented at the 47th Society of Gynecologic Oncology meeting held in San Diego, found that women with ovarian cancer who received statin therapy in tandem with their cancer treatment had better survival.

The cancer drug, best known as a game-changer for chronic myeloid leukemia, lowers insulin resistance through a similar mechanism as TZDs without the negative effects.

What we're reading, March 28, 2016: Covered California mishap with insured consumers' tax forms; Ted Cruz needs to outline his Obamacare replacement plan; and Google's life sciences startup runs into trouble.

What we're reading, March 25, 2016: Congress went on its spring recess without voting on Zika emergency funding; HealthCare.gov has more than 300 cybersecurity incidents; and Indiana's Medicaid expansion model has caught the attention of other conservative states.

What we're reading, March 24, 2016: Valeant doubles the price of aid-in-dying drug; the Supreme Court seems split on contraception case; and less than 3% of Americans meet qualifications for a healthy lifestyle.